Business Context and Reporting Period
Aquestive Therapeutics, Inc. (AQST) filed a Form 8-K on June 13, 2025, reporting a significant regulatory milestone. The filing discloses a press release issued on June 16, 2025, regarding the Company's New Drug Application (NDA) for Anaphylm.
Key Financial Metrics
This filing is a current report focused on regulatory disclosure and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the acceptance of the NDA for Anaphylm by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026. If approved, Anaphylm would become the first and only orally delivered epinephrine option for treating severe allergic reactions, including anaphylaxis, in the United States.
Guidance, Outlook, and Risks
Outlook: The Company anticipates a regulatory decision by the PDUFA target date of January 31, 2026.
Risks: The filing notes that the information is not deemed "filed" under Section 18 of the Exchange Act, limiting liability. The primary contingency remains the FDA's final approval decision; the filing does not guarantee approval.
Investor Verification Checklist
- Verify the PDUFA target action date of January 31, 2026, for the Anaphylm NDA.
- Confirm the status of the FDA review process for orally delivered epinephrine treatments.
- Review the attached press release (Exhibit 99.1) for detailed clinical data supporting the NDA.
- Monitor subsequent filings for the final FDA decision and potential commercialization timelines.